<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614132</url>
  </required_header>
  <id_info>
    <org_study_id>NOA-07</org_study_id>
    <nct_id>NCT01614132</nct_id>
  </id_info>
  <brief_title>Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults</brief_title>
  <acronym>NOA-07</acronym>
  <official_title>Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combination of a radiochemotherapy
      (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and CCNU) in
      adult patients with medulloblastoma is tolerable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As medulloblastoma in adult patients are very rare (1.1% of all brain tumors), adults are
      often treated in the scope of expanded access treatments or within pediatric studies;
      although, it is not known whether medulloblastomas act in the same way in adulthood and in
      childhood. This is the first study to investigate the significance of a combination of a
      radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin,
      cisplatin and CCNU) in adult patients with medulloblastoma with the purpose to have a
      starting point for the development of chemotherapeutical protocols in adults.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility of the adjuvant chemotherapy</measure>
    <time_frame>participants will be followed for the duration of chemo therapy, an expected average of 1 year</time_frame>
    <description>The main objective is the feasibility of the adjuvant chemotherapy which has gained the best results when combined with radiotherapy so far.
The present protocol is primarily to determine the number of interruptions of the maintenance chemotherapy due to toxicity and the kind of toxicity .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of performable cycles in chemo therapy</measure>
    <time_frame>participants will be followed for the duration of chemo therapy, an expected average of 6 months</time_frame>
    <description>It should be determined how many cycles in the maintenance chemotherapy are feasible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 and 5 years progression-free survival</measure>
    <time_frame>participants will be followed for the duration of chemo therapy and in the follow-up periode, an expected average of 3 to 5 years</time_frame>
    <description>The 3 and 5-years rate of progression-free survival (pfs) should be determined for adult patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>participants will be followed for the duration of chemo therapy and in the follow-up periode, an expected average of 3 to 5 years</time_frame>
    <description>The event-free survival (efs) should be determined for adult patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>participants will be followed for the duration of chemo therapy and in the follow-up periode, an expected average of 3 to 5 years</time_frame>
    <description>The overall survival (os) should be determined for adult patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>course of cognitive performance/QoL</measure>
    <time_frame>participants will be followed for the duration of chemo therapy and in the follow-up periode, an expected average of 3 to 5 years</time_frame>
    <description>The course of the cognitive performance and the quality of life should be observed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Medulloblastoma</condition>
  <arm_group>
    <arm_group_label>Vincristin, CCNU, cis-platin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy and concomitant chemotherapy (7 cycles of 7 days):
2 mg/m2 vincristin i.v.
55,0 Gy Posterior cranial fossa (M0)
55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)
maintenance chemotherapy (8 cycles of 42 days):
once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.
once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance chemotherapy (vincristin, cisplatin and CCNU)</intervention_name>
    <description>maintenance chemotherapy of maximum of 8 cycles á 42 days</description>
    <arm_group_label>Vincristin, CCNU, cis-platin</arm_group_label>
    <other_name>Vincristin: L01CA02</other_name>
    <other_name>CCNU: Lomustin L01AD02</other_name>
    <other_name>cis-platin: L01XA01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy of the partial brain</description>
    <arm_group_label>Vincristin, CCNU, cis-platin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 years

          -  medulloblastoma (+/- postoperative residual tumor, M0) or medulloblastoma (+/-
             postoperative residual tumor, M1-M3) respectively

          -  primary diagnosis of the tumor

          -  no previous chemo- or radiation therapy

          -  Karnofsky-Index ≥ 70%

          -  WBC ≥ 3000/μl; thrombocytes ≥ 100 000/μl; Hb ≥ 10 g/dl

          -  creatinine =&lt; 1,5 ULN; Bilirubin =&lt; 1,5 ULN; GPT, GOT, AP =&lt; 2,5 ULN

          -  HIV and hepatitis B/C negative

          -  no factors / any medical condition affecting patient's compliance

          -  patient needs to fulfil protocol's requirements

          -  patient is willing to use highly effective methods of contraception during dosing and
             for 6 months after the last dose; women of child-bearing potential must have a
             negative hCG laboratory test at baseline; pregnancy tests must be repeated every 4
             weeks

          -  patient's written consent

        Exclusion Criteria:

          -  age &lt; 18 years

          -  histologically not confirmed Medulloblastoma

          -  by chemo- or radiotherapy treated recidive tumor

          -  other cancer (with exception of surgically cured carcinoma in situ of the cervix and
             non-melanocytic skin tumors)

          -  hypersensitivity or contraindication against one of the used drugs

          -  current or planned participation to another clinical trial during this study Any other
             condition which, in the opinion of the Investigator, would make the patient unsuitable
             for enrolment or could interfere with the patient participating in and completing the
             study

          -  Any medical condition associated with high medical risk or contraindicated to use
             chemotherapeutic agents as indicated in current product package insert

          -  Pregnant or nursing (lactating) women; women or men not willing to use a highly
             effective methods of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University of Regensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vivantes Netzwerk für Gesundheit GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-von-Guericke Universität</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Peter Hau</investigator_full_name>
    <investigator_title>Head, Clinical Neurooncology</investigator_title>
  </responsible_party>
  <keyword>medulloblastoma</keyword>
  <keyword>CNS</keyword>
  <keyword>malignant neoplasm</keyword>
  <keyword>NOA</keyword>
  <keyword>neuroectodermal tumor</keyword>
  <keyword>Vincristin</keyword>
  <keyword>CCNU</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Lomustine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

